| Tebas, Pablo |
NCT04636437: Doravirine for Persons With Excessive Weight Gain on Integrase Inhibitors and Tenofovir Alafenamide |
|
|
| Active, not recruiting | 4 | 222 | US | Doravirine 100 Mg, Tenofovir alafenamide/emtricitabine, tenofovir alafenamide/lamivudine, Integrase strand transfer inhibitors, tenofovir disproxil fumarate/emtricitabine, tenofovir disproxil fumarate/lamivudine | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 11/24 | 11/24 | | |
NCT04060316: GLS-1200 Topical Nasal Spray to Prevent Sinusitis After Endoscopic Sinus Surgery |
|
|
| Not yet recruiting | 2 | 99 | US | GLS-1200, Placebo, Sterile Saline | GeneOne Life Science, Inc. | Sinusitis Chronic | 12/23 | 09/24 | | |
NCT03739996: Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1 |
|
|
| Completed | 2 | 75 | US | Oral Cabotegravir (CAB), Nucleoside Reverse Transcriptase Inhibitors (NRTIs), Long-Acting Injectable Cabotegravir (CAB LA), VRC07-523LS, VRC-HIVMAB075-00-AB, Standard of Care (SOC) Oral ART | National Institute of Allergy and Infectious Diseases (NIAID), ViiV Healthcare | HIV Infections | 04/24 | 04/24 | | |
BEAT-2, NCT03588715: Peg-Interferon Alpha 2b Combined With Two Intravenous Broadly HIV-1 Neutralizing Antibodies 3BNC117 and 10-1074 |
|
|
| Active, not recruiting | 1 | 15 | US | Pegylated Interferon alpha 2b (peg-IFN-α2b), Pegintron, 3BNC117 + 10-1074, Broadly Neutralizing Antibodies | Luis Montaner, University of Pennsylvania, Philadelphia Fight, Rockefeller University, Merck Sharp & Dohme LLC, National Institute of Allergy and Infectious Diseases (NIAID) | HIV, HIV/AIDS, HIV-1 Infection | 12/21 | 10/22 | | |
| Terminated | 1 | 52 | US | SAR441236, Placebo | National Institute of Allergy and Infectious Diseases (NIAID), Sanofi, ModeX Therapeutics | HIV-1-infection | 04/22 | 04/22 | | |
| Active, not recruiting | 1 | 61 | US | dMAb AZD5396, dMAb AZD8076, CELLECTRA™ 2000 with Side Port needle, OpBlock 0078 Electroporation device, Hylenex, CELLECTRA™ 2000 with Side Port needle, OpBlock 0070 Electroporation device | Pablo Tebas, The Wistar Institute, AstraZeneca, Inovio Pharmaceuticals | Healthy Volunteers | 09/25 | 09/25 | | |
| Active, not recruiting | 1 | 12 | US | CD4 CAR+CCR5 ZFN T-cells | University of Pennsylvania | Hiv | 12/26 | 12/27 | | |
NCT00031408: Consent for Use of Stored Patient Specimens for Future Testing |
|
|
| Recruiting | N/A | 30000 | US | | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 12/27 | 12/27 | | |
| Quinn, Joseph |
NCT03655236: PROSEEK: A Phase 2 Study In Early Parkinson's Disease Patients Evaluating The Safety And Efficacy Of Abl Tyrosine Kinase Inhibition Using K0706 |
|
|
| Terminated | 2 | 513 | Europe, US, RoW | K0706, placebo | Sun Pharma Advanced Research Company Limited | Early Parkinson Disease | 04/24 | 06/24 | | |
NCT06171724: Ashwagandha Pharmacokinetics Study in Older Adults |
|
|
| Recruiting | 1 | 12 | US | Shoden 240 mg, Shoden 480 mg | Oregon Health and Science University, National Center for Advancing Translational Sciences (NCATS) | Healthy, Aging | 08/25 | 08/25 | | |
NCT05591027: Safety and Target Engagement of Centella Asiatica in Cognitive Impairment |
|
|
| Recruiting | 1 | 48 | US | Centella asiatica product, CAP, Placebo | Oregon Health and Science University, Alzheimer's Association | Mild Cognitive Impairment, Alzheimer's Disease | 11/25 | 03/26 | | |
NCT06772220: Pilot Study of Open Label Homocysteine Management Therapy in Levodopa-treated Parkinson's Disease |
|
|
| Recruiting | N/A | 150 | US | Folic Acid 1 MG, Vitamin B6 25 MG, Vitamin B12 | Oregon Health and Science University | Parkinson&Amp;#39;s Disease | 12/25 | 12/25 | | |
NCT04994015: Parkinson's Foundation PD GENEration Genetic Registry |
|
|
| Recruiting | N/A | 25000 | Canada, US, RoW | Lab Assay for seven genetic variants for Parkinson's Disease | Parkinson's Foundation, Indiana University, Fulgent Genetics, The Parkinson Study Group | Parkinson's Disease | 12/24 | 06/25 | | |
NCT05699460: Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy |
|
|
| Active, not recruiting | N/A | 150 | Europe, US | This is an observational study. | Asklepios Biopharmaceutical, Inc. | Parkinson's Disease, Multiple System Atrophy, Parkinson Variant, Multiple System Atrophy | 08/25 | 10/25 | | |
NCT00031408: Consent for Use of Stored Patient Specimens for Future Testing |
|
|
| Recruiting | N/A | 30000 | US | | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 12/27 | 12/27 | | |
| O'Connell, Maureen |
NCT00031408: Consent for Use of Stored Patient Specimens for Future Testing |
|
|
| Recruiting | N/A | 30000 | US | | Advancing Clinical Therapeutics Globally for HIV/AIDS and Other Infections, National Institute of Allergy and Infectious Diseases (NIAID) | HIV Infections | 12/27 | 12/27 | | |
